Mechanism of Toxin's Inflammatory Effect on Lungs
A study released December 23rd 2014 describes a never-before-seen mechanism by which a bacterial toxin leads to severe inflammation in asthma and other acute and chronic pulmonary diseases. Researchers from The University of Texas Health Science Center at San Antonio said the discovery could result in development of therapeutic strategies that improve health in individuals who suffer from airway diseases.
A release from the university explains that the offending party is the Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome (CARDS) toxin. The CARDS toxin, discovered at the Health Science Center in 2006, is considered the first major bacterial respiratory toxin discovered since the days of diphtheria and pertussis.
Persistent and harmful
M. pneumoniaeis a common and persistent infection in the lungs and airway. Once there, it produces the CARDS toxin and a cascade of harmful effects. Specifically, CARDS toxin reacts with NALP3, a key molecule that regulates inflammatory pathways, leading to excessive activation of pro-inflammatory reactions.
The release quotes study author Joel B. Baseman, Ph.D., professor of microbiology and immunology in the School of Medicine at the UT Health Science Center and director of the Center for Airway Inflammation Research (cAIR), as saying, “Inflammation is important for self-protection from infection and any injury, but when a microbial factor such as the CARDS toxin controls inflammation, bad things happen. Through this mechanism, CARDS toxin triggers exaggerated and prolonged inflammation that results in tissue injury, airway narrowing, mucus hypersecretion, wheezing and coughing.”
“Because M. pneumoniae infections occur so frequently in children and adults and CARDS toxin is such a powerful inducer of inflammation, it is likely that co-infections involving M. pneumoniae, CARDS toxin and other respiratory pathogens result in enhanced severity of disease,” said Santanu Bose, Ph.D., study co-author and associate professor at Washington State University.
“Now that we have identified this pathway of disease development, our goal is to prevent the wide range of airway pathologies caused by CARDS toxin with drugs, vaccines and protective antibodies,” said study co-author Thirumalai R. Kannan, Ph.D., associate professor/research in the Department of Microbiology and Immunology at the UT Health Science Center and also a member of cAIR. “We are undertaking those studies now.”